Siemens Healthineers Completes Acquisition of Varian, Strengthening its Position as a Holistic Partner in Healthcare

Siemens HealthineersSiemens Healthineers AG (Frankfurt: SHL) announced that it has successfully completed the acquisition of Varian Medical Systems, Inc. ("Varian"). The acquisition was previously announced on August 2, 2020.

"With Varian, Siemens Healthineers has the most comprehensive portfolio in the MedTech sector, which offers the company considerable potential for value creation. With a highly integrated approach, Siemens Healthineers will take the global fight against cancer to a new level," said Prof. Dr. Ralf P. Thomas, Chairman of the Supervisory Board of Siemens Healthineers AG.

"With the completion of this transaction, we are now best-positioned to take two leaps together: a leap in cancer care and a leap in our impact on healthcare overall. Together, we are establishing a strong and trusted partner capable of supporting customers and patients along the entire cancer care continuum as well as through all major clinical pathways," said Dr. Bernd Montag, CEO of Siemens Healthineers AG.

"Through the transformative combination of Varian and Siemens Healthineers, our united company will address the growing need for personalized, data-driven diagnosis and precision cancer care that enables us to fight back against globally increasing cancer rates," said Chris Toth, CEO of Varian, a Siemens Healthineers company. "By bringing together our unique and highly complementary portfolios and capabilities, we will support oncology clinicians and patients in achieving better outcomes and move even closer to achieving our vision of a world without fear of cancer."

The combined company is creating a unique, highly integrated portfolio of imaging, laboratory diagnostics, artificial intelligence and treatment for the global fight against cancer with significant potential for increased value creation. The acquisition aligns perfectly with the "Upgrading" phase of Siemens Healthineers strategy. With today's closing of the acquisition, Varian is expected to positively contribute to Siemens Healthineers adjusted basic earnings per share(1) within the first 12 months. Additionally, Siemens Healthineers aims for EBIT synergies of at least EUR 300 million per annum in fiscal year 2025.

Varian and Siemens Healthineers are building on the long-standing strategic partnership called "EnVision" to establish a comprehensive digital, diagnostic and therapeutic ecosystem that includes treatment management. With Varian, Siemens Healthineers will leverage AI-assisted analytics to advance the development and delivery of data-driven precision care and redefine cancer diagnosis, care delivery and post-treatment survivorship. Through early and accurate detection as well as more efficient diagnosis, increased treatment quality and access, Siemens Healthineers will support and accelerate Varian's mission to reduce uncertainty for cancer patients and increase the level of cancer survivorship.

Siemens Healthineers completed the first phase of its Strategy 2025 at the end of fiscal year 2019, during which the company successfully implemented its IPO and launched important product innovations such as the AI-Rad Companions. With the start of fiscal year 2020, Siemens Healthineers has entered the second phase of its "Siemens Healthineers Strategy 2025." This "Upgrading" phase will take Siemens Healthineers to the next level of profitable growth. With the acquisitions of Corindus and ECG Management Consultants, the company has already strengthened its offerings in adjacent growth areas. And, with Varian, Siemens Healthineers is well-positioned to grow in existing markets, enter adjacent fields and make new markets.

Varian's common stock ceased trading on the New York Stock Exchange prior to the opening of trading.

About Siemens Healthineers

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalising healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients. In fiscal 2020, which ended on September 30, 2020, Siemens Healthineers, which has approximately 54,000 employees worldwide, generated revenue of €14.5 billion and adjusted EBIT of €2.2 billion.

1. Before purchase price allocation effects, transaction, integration, retention and restructuring costs as well as gains and losses from divestments.

Most Popular Now

AI Predicts Lung Cancer Risk

An artificial intelligence (AI) program accurately predicts the risk that lung nodules detected on screening CT will become cancerous, according to a study published in the journal Radiology. Lung cancer is...

EU Health Policy Platform Calls for Prop…

The European Commission is inviting public health stakeholders to submit initiatives for anew cycle of Thematic Networks under the EU Health Policy Platform. The purpose of a Thematic Network is...

What Next for Social Care?

Highland Marketing's advisory board welcomed Jane Brightman, social care lead at Institute of Health and Social Care Management, to discuss the sector and its technology needs. A lot of hope...

Philips Introduces the New Spectral Comp…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced its newest solution for precision diagnosis with the global introduction of its spectral detector-based Spectral Computed...

Web-Based System Developed to Give Care …

Black Country Pathology Services has worked with CliniSys to create the ICE Portal, a web-based application that makes it easy for care homes, or other community care settings, to be...

Grand Challenge Research Harnesses AI to…

Breast cancer has recently overtaken lung cancer to become the most common cancer globally, according to the World Health Organization. Advancing the fight against breast cancer, the BreastPathQ Challenge was...

UCSF Improves Fetal Heart Defect Detecti…

UC San Francisco researchers have found a way to double doctors' accuracy in detecting the vast majority of complex fetal heart defects in utero - when interventions could either correct...

MEDICA 2021 + COMPAMED 2021: Medical Tec…

15 - 18 November 2021, Düsseldorf, Germany. The date for the globally leading live platforms for the medical technology industry remains a fixed feature in everybody's calendar this year too. The...

New AI Technology Protects Privacy

Digital medicine is opening up entirely new possibilities. For example, it can detect tumors at an early stage. But the effectiveness of new AI algorithms depends on the quantity and...

GP use of Tech Helps Prevent Prescribing…

Academic analysis shows primary care prescribers have been preventing adverse drug reactions, harm and hospital admissions through safer prescribing, after using prescribing tech. The company behind the system also reveals...

Online Survey Successful in Gathering CO…

A pilot project using an online survey to gather data on COVID-19 symptoms received more than 87,000 responses from around the world, providing important insight into the spread of disease...